Most cited papers from UK Health Security Agency

UK Health Security Agency

What are the most cited papers from UK Health Security Agency?

The most cited paper from UK Health Security Agency is "Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study" (Tommy Nyberg et al., 2022), with 1,307 citations. Next come "Clinical features and management of human monkeypox: a retrospective observational study in the UK" (1,299) and "The 2023 report of the Lancet Countdown on health and climate change: the imperative for a health-centred response in a world facing irreversible harms" (1,254).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 59 papers. Every paper with more than 120 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study Tommy Nyberg et al. · The Lancet Open access	16 Mar 2022	1,307
2	Clinical features and management of human monkeypox: a retrospective observational study in the UK Hugh Adler et al. · The Lancet Infectious Diseases Open access139 authors	24 May 2022	1,299
3	The 2023 report of the Lancet Countdown on health and climate change: the imperative for a health-centred response in a world facing irreversible harms Marina B Romanello et al. · The Lancet Open access114 authors	14 Nov 2023	1,254
4	Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression Daniel R Feikin, Melissa M Higdon, Laith J Abu-Raddad et al. · The Lancet ReviewOpen access	22 Feb 2022	1,235
5	Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection Victoria Jane Hall et al. · New England Journal of Medicine Open access	16 Feb 2022	757
6	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial Alasdair P S Munro et al. · The Lancet Open access308 authors	Dec 2021	699
7	Influenza Timothy M. Uyeki, David S.C. Hui, Maria Cristina Fleischmann Alves Zambon et al. · The Lancet Open access	Aug 2022	568
8	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial Munro, APS et al. · Sussex Research Online (University of Sussex) Open access	2 Dec 2021	445
9	The potential impacts of micro-and-nano plastics on various organ systems in humans Nurshad Ali, Jenny Katsouli, Emma L. Marczylo et al. · EBioMedicine Open access	6 Dec 2023	395
10	Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England Nick Andrews, Julia Stowe, Freja Kirsebom et al. · Nature Medicine Open access	14 Jan 2022	391
11	Community transmission of monkeypox in the United Kingdom, April to May 2022 Roberto Vivancos et al. · Eurosurveillance Open access	2 Jun 2022	388
12	Immune boosting by B.1.1.529 ( Omicron) depends on previous SARS-CoV-2 exposure Catherine J. Reynolds et al. · Science Open access148 authors	14 Jun 2022	371
13	Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study Megan Bardsley, Roger Morbey, Helen E. Hughes et al. · The Lancet Infectious Diseases Open access	2 Sep 2022	328
14	The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis Timothy M Walker et al. · The Lancet Microbe Open access232 authors	8 Mar 2022	305
15	Emergence of methicillin resistance predates the clinical use of antibiotics Jesper Larsen et al. · Nature Open access	5 Jan 2022	292
16	Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021 Margaux M. I. Meslé et al. · Eurosurveillance Open access	25 Nov 2021	282
17	Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis William S. Hart, Elizabeth J. Miller, Nick J Andrews et al. · The Lancet Infectious Diseases Open access	14 Feb 2022	268
18	Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review Alison F Crawshaw, Farah Yasmin, Anna C. Deal et al. · The Lancet Infectious Diseases ReviewOpen access	13 Apr 2022	254
19	Population genomics confirms acquisition of drug-resistant Aspergillus fumigatus infection by humans from the environment Johanna L. Rhodes et al. · Nature Microbiology Open access	25 Apr 2022	251
20	Understanding and managing uncertainty and variability for wastewater monitoring beyond the pandemic: Lessons learned from the United Kingdom national COVID-19 surveillance programmes Matthew J. Wade et al. · Journal of Hazardous Materials Open access	8 Oct 2021	249
21	Chemicals in European residences – Part I: A review of emissions, concentrations and health effects of volatile organic compounds (VOCs) Christos H. Halios, Charlotte Landeg-Cox, Scott D. Lowther et al. · The Science of The Total Environment Open access	24 May 2022	231
22	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial Arabella S. V. Stuart et al. · The Lancet Open access	6 Dec 2021	227
23	Indoor air quality guidelines from across the world: An appraisal considering energy saving, health, productivity, and comfort Sani Dimitroulopoulou, Marzenna R. Dudzińska, Lars Gunnarsen et al. · Environment International Open access	31 Jul 2023	223
24	WHO global research priorities for antimicrobial resistance in human health Silvia Bertagnolio et al. · The Lancet Microbe Open access284 authors	13 Aug 2024	217
25	Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks Alpha Kabinet Kéita et al. · Nature Open access	15 Sep 2021	217
26	Advancing One human–animal–environment Health for global health security: what does the evidence say? Jakob Zinsstag et al. · The Lancet Open access	19 Jan 2023	215
27	Increase in invasive group A streptococcal infection notifications, England, 2022 Rebecca L. Guy, Katherine L. Henderson, Juliana Coelho et al. · Eurosurveillance Open access	5 Jan 2023	214
28	APOBEC3 deaminase editing in mpox virus as evidence for sustained human transmission since at least 2016 Aine Niamh O’Toole et al. · Science Open access	2 Nov 2023	213
29	A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes Theo Sanderson, Ryan Hisner, I’ah Donovan-Banfield et al. · Nature Open access	25 Sep 2023	211
30	Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern Nick J Andrews et al. · medRxiv PreprintOpen access	14 Dec 2021	191
31	Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups Heather Whitaker et al. · Journal of Infection Open access	3 Jan 2022	182
32	Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial Alasdair Peter Stuart Munro et al. · The Lancet Infectious Diseases Open access364 authors	9 May 2022	180
33	Adeno-associated virus 2 infection in children with non-A–E hepatitis Antonia Ying Wai Ho et al. · Nature Open access533 authors	30 Mar 2023	177
34	COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England Freja Cordelia Møller Kirsebom, Nick J Andrews, Julia Stowe et al. · The Lancet Infectious Diseases Open access	24 May 2022	176
35	Effectiveness of COVID-19 vaccines against Omicron and Delta hospitalisation, a test negative case-control study Julia Stowe, Nick J Andrews, Freja Cordelia Møller Kirsebom et al. · Nature Communications Open access	30 Sep 2022	173
36	Trends in invasive bacterial diseases during the first 2 years of the COVID-19 pandemic: analyses of prospective surveillance data from 30 countries and territories in the IRIS Consortium David R. Shaw et al. · The Lancet Digital Health Open access	27 Jul 2023	170
37	Transmission of monkeypox virus through sexual contact – A novel route of infection Joseph Heskin, Amy Belfield, Charlotte Milne et al. · Journal of Infection Open access	Jun 2022	169
38	The origins and molecular evolution of SARS-CoV-2 lineage B.1.1.7 in the UK Verity Hill et al. · Virus Evolution Open access	Jul 2022	168
39	Global and regional governance of One Health and implications for global health security Azza Elnaiem et al. · The Lancet Open access	19 Jan 2023	163
40	Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational study Marta Bertran, Nick J Andrews, Chloe Davison et al. · The Lancet Infectious Diseases Open access	13 Mar 2023	162
41	Wastewater monitoring can anchor global disease surveillance systems Aparna P. Keshaviah et al. · The Lancet Global Health Open access	17 May 2023	152
42	Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance Dimitra Klapsa et al. · The Lancet Open access	Oct 2022	151
43	Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants Catherine J. Reynolds et al. · Science Open access	14 Jan 2022	149
44	Context-specific emergence and growth of the SARS-CoV-2 Delta variant John T. McCrone et al. · Nature Open access	11 Aug 2022	145
45	A systematic review of communication interventions for countering vaccine misinformation Hannah S. Whitehead, Clare E. French, Deborah M Caldwell et al. · Vaccine ReviewOpen access	2023	142
46	Global phylogeny of Treponema pallidum lineages reveals recent expansion and spread of contemporary syphilis Mathew A. Beale et al. · Nature Microbiology Open access	24 Nov 2021	141
47	Genomic investigations of unexplained acute hepatitis in children Sofia Morfopoulou et al. · Nature Open access683 authors	30 Mar 2023	139
48	SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease Eleanor Barnes et al. · Nature Medicine Open access159 authors	Jul 2023	137
49	Transmission dynamics of monkeypox in the United Kingdom: contact tracing study Thomas Ward, Rachel Christie, Robert Stephen Paton et al. · BMJ Open access	2 Nov 2022	136
50	Onset and window of SARS-CoV-2 infectiousness and temporal correlation with symptom onset: a prospective, longitudinal, community cohort study Seran Hakki et al. · The Lancet Respiratory Medicine Open access	18 Aug 2022	136

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.